By targeting CD163 or triggering receptor expressed on myeloid cells-1 (TREM-1) (known as PY159) in TAMs with monoclonal antibodies, TAMs in the TME of HCC can be eliminated or reprogrammed, potentially reversing the immunosuppressive environment of HCC’s TME [59,71]. Here, TREM1 is linked to hepatocellular carcinoma.